Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 5, Issue 4, Pages 350-356Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2005.04.007
Keywords
-
Categories
Ask authors/readers for more resources
Since the discovery that activating mutations of the Ras GTPase were associated with 30% or more of human cancers, the RAF/MEK/ERK pathway has been the focus of intense drug discovery effort. Within the new class of molecularly targeted anti-cancer agents progressing through the late stages of clinical development, BAY 43-9006 and PD0325901 have shown considerable promise,
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available